FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA)
J. Clin. Oncol 2021 Feb 08;[EPub Ahead of Print], JR Hecht, S Lonardi, J Bendell, HW Sim, T Macarulla, CD Lopez, E Van Cutsem, AJ Muñoz Martin, JO Park, R Greil, H Wang, RR Hozak, I Gueorguieva, Y Lin, S Rao, BY RyooFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.